Summary
This technical report discusses the critical objective of optimizing efficiency in clinical trials by reducing 'white space', which refers to delays and bottlenecks within and between trial phases. It outlines how inefficiencies can negatively impact timelines and expenditures, ultimately affecting the return on investment for drug sponsors. The report presents a framework for minimizing these delays through targeted initiatives, including the adoption of best practices, increased automation, and streamlined technology integration. It emphasizes the importance of collaboration with experienced contract research organizations (CROs) to enhance trial efficiency. The report also highlights the rising complexity in drug discovery, driven by scientific advances and the need for innovative trial designs. It provides actionable recommendations for drug sponsors to improve productivity throughout the clinical trial process, focusing on proactive planning, parallel processing, advanced analytics, and cross-functional alignment. By implementing these strategies, sponsors can effectively reduce white space and enhance the overall quality of clinical trials.
